Fifty seven years of follow-up of the Israeli cohort of Laron Syndrome patients-From discovery to treatment

Growth Hormone and IGF Research

Volumn 28, Issue , 2016, Pages 53-56

  Laron, Zvi ^a   Kauli, Rivka ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Dwarfism; GH insensitivity; IGF I; IGF I treatment; Laron syndrome; Obesity

Indexed keywords

ADULT; ARTICLE; CHILD; CLINICAL FEATURE; COHORT ANALYSIS; DIABETES MELLITUS; DISEASE SEVERITY; DWARFISM; ETHNICITY; FEMALE; FOLLOW UP; HUMAN; ISRAELI; LARON SYNDROME; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OBESITY; PRIORITY JOURNAL; SCHOOL CHILD; SEX DIFFERENCE; YOUNG ADULT; ADOLESCENT; GENETICS; INFANT; ISRAEL; JEW; METABOLISM; MIDDLE EAST; NEOPLASM; NEWBORN; PRESCHOOL CHILD; PROTECTION;

GROWTH HORMONE RECEPTOR; SOMATOMEDIN C;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; INFANT, NEWBORN; INSULIN-LIKE GROWTH FACTOR I; ISRAEL; JEWS; LARON SYNDROME; MALE; MIDDLE AGED; MIDDLE EAST; NEOPLASMS; PROTECTIVE FACTORS; RECEPTORS, SOMATOTROPIN; YOUNG ADULT;

EID: 84939613197     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2015.08.004     Document Type: Article

References (40)

1. Laron Z., Pertzelan A., Mannheimer S. Genetic pituitary dwarfism with high serum concentration of growth hormone. A new inborn error of metabolism?. Isr. J. Med. Sci. 1966, 2:153-155.
2. Laron Z., Pertzelan A., Karp M. Pituitary dwarfism with high serum levels of growth hormone. Isr. J. Med. Sci. 1968, 4:883-894.
3. Laron Z. Laron type dwarfism (hereditary somatomedin deficiency): a review. Advances in Internal Medicine and Pediatrics 1984, 51:117-150. Springer-Verlag, Berlin-Heidelberg. P. Frick, G.A. Von Harnack, G.A. Koschsiek, A. Prader (Eds.).
4. Glick S.M., Roth J., Yalow R.S., Berson S.A. Immunoassay of human growth hormone in plasma. Nature 1963, 199:784-788.
5. Eshet R., Laron Z., Brown M., Arnon R. Immunoreactive properties of the plasma hGH from patients with the syndrome of familial dwarfism and high plasma IR-hGH. J. Clin. Endocrinol. Metab. 1973, 37:819-821.
6. Eshet R., Peleg S., Josefsberg Z., Fuchs C., Arnon R., Laron Z. Some properties of the plasma hGH activity in patients with Laron-type dwarfism determined by a radioreceptor assay using human liver tissue. Horm. Res. 1985, 22:276-283.
7. Russell R.E., Parks J.S., McKean M.C., Bell G.I., Keret R., Kelijman M., Laron Z. Laron-type dwarfism is associated with normal growth hormone and insulin-like growth factor I gene restriction patterns. Isr. J. Med. Sci. 1989, 25:342-344.
8. Laron Z., Pertzelan A., Karp M., Kowadlo-Silbergeld A., Daughaday W.H. Administration of growth hormone to patients with familial dwarfism with high plasma immunoreactive growth hormone. Measurement of sulfation factor, metabolic, and linear growth responses. J. Clin. Endocrinol. Metab. 1971, 33:332-342.
9. Elders M.J., Garland J.T., Daughaday W.H., Fisher D.A., Whitney J.E., Hughes E.R. Larons's dwarfism: studies on the nature of the defect. J. Pediatr. 1973, 83:253-263.
10. Eshet R., Laron Z., Pertzelan A., Dintzman M. Defect of human growth hormone in the liver of two patients with Laron type dwarfism. Isr. J. Med. Sci. 1984, 20:8-11.
11. Leung D.W., Spencer S.A., Cachianes G., Hammonds R.G., Collins C., Henzel W.J., Barnard R., Waters M.J., Woods W.I. Growth hormone receptor and serum binding protein: purification, cloning and expression. Nature 1987, 330:537-543.
12. Godowski P.J., Leung D.W., Meachem L.R., Galgani J.P., Hellmiss R., Keret R., Rotwein P.S., Parks J.S., Laron Z., Wood W.I. Characterization of the human growth hormone receptor gene and demonstration of a partial gene deletion in two patients with Laron type dwarfism. Proc. Natl. Acad. Sci. U. S. A. 1989, 86:8083-8087.
13. Amselem S., Duquesnoy P., Attre O., Novelli G., Bousnina S., Postel-Vinay M.C., Goosens M. Laron dwarfism and mutations of the growth hormone-receptor gene. N. Engl. J. Med. 1989, 321:989-995.
14. Shevah O., Laron Z. Genetic aspects. Laron Syndrome - From Man to Mouse 2011, 29-52. Springer Verlag, Berlin Heidelberg. Z. Laron, J. Kopchick (Eds.).
15. Laron Z. Laron syndrome (primary growth hormone resistance or insensitivity): the personal experience 1958-2003. J. Clin. Endocrinol. Metab. 2004, 89(3):1031-1044.
16. Laron syndrome from man to mouse. Genetics, Pathophysiology Aspects, Treatment and Experimental 2011, 531. Springer Verlag, Berlin Heidelberg. 1st ed. Z. Laron, J.J. Kopchick (Eds.).
17. Laron Z., Iluz M., Kauli R. Head circumference in untreated and IGF-I treated patients with Laron syndrome. Comparison with untreated and hGH-treated children with isolated growth hormone deficiency. Growth Hormon. IGF Res. 2012, 22:49-52.
18. Laron Z., Kauli R. Linear growth pattern of untreated Laron syndrome patients. Laron Syndrome - From Man to Mouse 2011, 63-89. Springer Verlag, Berlin Heidelberg. Z. Laron, J. Kopchick (Eds.).
19. Laron Z., Lilos P., Klinger B. Growth curves for Laron syndrome. Arch. Dis. Child. 1993, 68:768-770.
20. Laron Z., Silbergeld A. A simple diagnostic screening test for children with short stature - with emphasis on genetic defects along the GH axis. Pediatr. Endocrinol. Rev. 2006, 4:96-98.
21. Domené H.M., Scaglia P.A., Jasper H.G. Deficiency of the insulin-like growth factor-binding protein acid-labile subunit (ALS) of the circulating ternary complex in children with short stature. Pediatr. Endocrinol. Rev. 2010, 7:339-346.
22. Laron Z., Sarel R., Pertzelan A. Puberty in Laron-type dwarfism. Eur. J. Pediatr. 1980, 134:79-83.
23. Laron Z., Klinger B. Body fat in Laron syndrome patients: effect of insulin-like growth factor I treatment. Horm. Res. 1993, 40:16-22.
24. Laron Z., Ginsberg S., Lilos P., Arbiv M., Vaissman N. Body composition in untreated adult patients with Laron syndrome (primary GH insensitivity). Clin. Endocrinol. 2006, 65:114-117.
25. Laron Z., Ginsberg S., Webb M. Nonalcoholic fatty liver in patients with Laron syndrome and GH gene deletion. Prelim. Rep. IGF Res. 2008, 18:434-438.
26. Ginsberg S., Laron Z., Arbiv M., Vaisman N. The obesity of patients with Laron syndrome is not associated with excessive nutritional intake. Obes. Res. Clin. Pract. 2009, 3:3-8.
27. Kanety H., Hemi R., Ginsberg S., Pariente C., Yissachar E., Barchod E., Funahashi T., Laron Z. Total and high molecular weight adiponectin are elevated in patients with Laron syndrome despite marked obesity. Eur. J. Endocrinol. 2009, 161:837-844.
28. Laron Z. Psychological aspects in patients with Laron syndrome. Laron Syndrome - From Man to Mouse 2011, 325-333. Springer Verlag, Berlin Heidelberg. Z. Laron, J. Kopchick (Eds.).
29. Kornreich L., Horev G., Schwarz M., Karmazyn B., Laron Z. Craniofacial and brain abnormalities in Laron syndrome (primary growth hormone in sensitivity). Eur. J. Endocrinol. 2002, 146:499-503.
30. Kornreich L., Horev G., Schwarz M., Karmazyn B., Laron Z. Pituitary size in patients with Laron syndrome (primary GH insensitivity). Eur. J. Endocrinol. 2003, 148:339-341.
31. Attias J., Zarchi O., Nageris B.I., Laron Z. Cochlear hearing loss in patients with Laron syndrome. Eur. Arch. Otorhinolaryngol. 2012, 269:461-466.
32. Laron Z. Insulin-like growth factor-I treatment of children with Laron syndrome (primary growth hormone insensitivity). Pediatr. Endocrinol. Rev. 2008, 5:766-771.
33. Laron Z. Emerging treatment options for patients with Laron syndrome. Expert Opin. Orphan Drugs 2014, 7:681-694.
34. Laron Z. If one daily injection of IGF-I has the same growth promoting effect as 2 injections a day, why continue to give two injections?. Pediatr. Endocrinol. Rev. 2013, 10:277-279.
35. Laron Z., Ginsberg S., Lilos P., Arbiv M., Vaisman N. Long-term IGF-I treatment of children with Laron syndrome increases adiposity. Growth Hormon. IGF Res. 2006, 16:61-64.
36. Laron Z., Klinger B. IGF-I treatment of adult patients with Laron syndrome: preliminary results. Clin. Endocrinol. (Oxf.) 1994, 41:631-638.
37. Guevara-Aguirre J., Balasubramanian P., Guevara-Aguirre M., Wei M., Madia F., Cheng C.-W., Hwang D., Martin-Montalvo A., Saavedra J., Ingles S., de Cabo R., Cohen P., Longo V.D. Growth hormone receptor deficiency is associated with a major reduction in pro-aging signalling, cancer and diabetes in humans. Sci. Transl. Med. 2011, 3(70). (70ra13). 10.1126/scitranslmed.3001845.
38. Shevah O., Laron Z. Patients with congenital deficiency of IGF-I seem protected from the development of malignancies. A preliminary report. Growth Hormon. IGF Res. 2007, 17:54-57.
39. Steuerman R., Shevah O., Laron Z. Congenital IGF-I deficiency tends to confer protection against postnatal development of malignancies. Eur. J. Endocrinol. 2011, 164:485-489.
40. Lapkina L., Laron Z., Werner H. Genome-wide analysis of cancer protection pathways in Laron syndrome patients. Growth Hormon. IGF Res. 2012, 22. (P01-22:S3).